Hims & Hers Sticking with Weight-Loss Even If GLP-1 Shortage Ends -- Market Talk

Dow Jones
2024-11-09

1421 ET - Hims & Hers Health has ample opportunities to grow its weight-loss offerings even after GLP-1 drugs are taken off the FDA's shortage list, TD Cowen analysts say in a research note after meeting with management. A key concern for the stock is how the weight-loss platform will grow in a world if Hims can no longer offer compounded GLP-1s, the analysts say. But management believes it can provide a variety of weight loss offerings, including oral medication, personalized dosages of compounded GLP-1s, branded GLP-1s and liraglutide, that will ultimately be more affordable than a traditional GLP-1 program, the analysts say. (dean.seal@wsj.com)

(END) Dow Jones Newswires

November 08, 2024 14:21 ET (19:21 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10